In:
PROTEOMICS – Clinical Applications, Wiley, Vol. 7, No. 9-10 ( 2013-10), p. 657-663
Abstract:
Most A lzheimer disease patients show deposition of amyloid β ( A β) peptide in blood vessels as well as the brain parenchyma. We previously found that vascular endothelial cells express amyloid β precursor protein ( APP ) 770, a different APP isoform from neuronal APP 695, and that they produce amyloid β peptide. We analyzed the glycosylation of APP 770 and found that O ‐glycosylated s APP 770 is preferentially processed by proteases for A β production. Because the soluble APP cleavage product s APP is considered to be a possible marker for A lzheimer disease diagnosis, s APP , consisting of a mixture of these variants, has been widely measured. We hypothesized that measurement of the endothelial APP 770 cleavage product in patients separately from that of neuronal APP 695 would enable us to discriminate between endothelial and neurological dysfunctions. Our recent findings, showing that the level of plasma s APP 770 is significantly higher in patients with acute coronary syndrome, raise the possibility that s APP 770 could be an indicator of endothelial dysfunction. In this review, we first describe the expression, glycosylation, and processing of APP 770, and then discuss s APP 770 as a novel biomarker candidate of acute coronary syndrome.
Type of Medium:
Online Resource
ISSN:
1862-8346
,
1862-8354
DOI:
10.1002/prca.v7.9-10
DOI:
10.1002/prca.201200135
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
2317130-3
Bookmarklink